Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research(2023)
Abstract
Our findings support novel insights into tremelimumab pharmacokinetics and exposure-response relationships in HCC and support the clinical utility of the STRIDE regimen in patients with uHCC.
MoreTranslated text
Key words
tremelimumab monotherapy,hepatocellular carcinoma,unresectable hepatocellular carcinoma,durvalumab,exposure-response
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined